Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
OBJECTIVE
The aim of this study is to evaluate the efficacy and safety of intrarenal bacillus Calmette-Guérin (BCG) instillation as a treatment for transitional cell carcinoma in situ (CIS) of the upper urinary tract.


METHODS
Diagnostic criteria of upper urinary tract CIS were (1) positive urinary cytology, (2) negative multiple random biopsy of the bladder and prostatic urethra, (3) negative radiographic findings in the upper urinary tract and (4) two serial positive cytologies in selective ipsilateral urine sampling from the pyeloureteral system. Eleven patients diagnosed as having upper urinary tract CIS were enrolled in this study. Thus, 11 renal units were treated with BCG instillation. After placing a 6-french Double-J stent, BCG (80 mg) in 40 ml saline was instilled into the bladder weekly, 6 times in total as one course.


RESULTS
At the end of one course, 9 cases showed negative urinary cytology. Among these 9 cases, 2 showed recurrence in the upper urinary tract after 4 months and 8 months of disease-free interval, respectively. These 2 cases have received an additional course of BCG instillation, but the urinary cytology did not normalize. Mean recurrence-free time was 19.6 months. Of the other 7 cases who responded to the first course of instillation, 6 cases were alive with no evidence of the disease. The remaining patient died of rectal cancer with no evidence of transitional cell carcinoma (TCC). Of the 2 cases who showed positive urinary cytology even after the first course, 1 underwent nephroureterectomy. The other case was diagnosed as having malignant lymphoma 3 months after the end of this instillation therapy, and he died of malignant lymphoma. As side effects, 8 cases (72.7%) showed bladder irritability, and 4 presented fever higher than 38 degrees C. However, no patient needed antitubercular treatment.


CONCLUSIONS
As for the short-term response, BCG instillation for the treatment of upper urinary tract CIS is considered to be effective and safe. Longer follow-up and further experience with this treatment are required.
Nonomura
N
N
Department of Urology, Osaka University Medical School, Suita City, Osaka, Japan. nono@uro.med.osaka-u.ac.jp
Ono
Y
Y
Nozawa
M
M
Fukui
T
T
Harada
Y
Y
Nishimura
K
K
Takaha
N
N
Takahara
S
S
Okuyama
A
A
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000453:epidemiology / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000453:epidemiology / Q000628:therapy*; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D007322:Instillation, Drug; D007680:Kidney Neoplasms / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D010477:Perfusion; D015607:Stents; D013997:Time Factors; D014516:Ureteral Neoplasms / Q000453:epidemiology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine